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Introduction
============

Retinoic acid (RA), which is derived from dietary vitamin A, plays an essential role in the maintenance of the differentiated state of epithelial cells and tissue remodeling \[[@r1]-[@r3]\]. The family of retinoic acid receptors (RARs) that includes the RARα, β and γ subtypes and associated alternatively spliced isoforms are the main mediators for the biologic effects of RA \[[@r4],[@r5]\]. RA and other natural and synthetic RAR agonists are well known to inhibit the growth of human breast tumor cell lines *in vitro* and in mouse xenograft models, a process that generally involves the induction of both apoptosis and cell-cycle arrest \[[@r6]-[@r12]\]. In addition, the absence of RARβ-dependent retinoid signaling has been associated with the development of carcinomas, including breast cancer, and resistance to the anti-cancer activity of RA \[[@r13]\]. Despite the potent growth-suppressing activity of retinoids on human breast cancer cell lines, this class of compounds has not shown relevant anti-cancer activity in the treatment of breast cancer \[[@r14],[@r15]\].

Recently, RAR-null mice have been used to address the role of the RARs in mammary gland development and the response of the gland to specific oncogenic insults \[[@r16],[@r17]\]. Ablation of RARα1 led to an increase in the density of the mammary epithelial tree and the content of luminal mammary progenitors, in addition to reducing the size of the mammary stem cell-containing compartment \[[@r17]\]. In contrast, loss of RARβ resulted in a delay in mammary tree development in the pubertal stage as a significant shortening of the distance between the lymph node and the terminal end buds were observed in the RARβ-null gland \[[@r16]\]. The developmental abnormalities observed in both RAR-deficient mouse models were transient since, as previously reported \[[@r18]-[@r20]\], the glands were fully functional at later stages of development. While ablation of RARα1 and β resulted in distinct developmental mammary gland abnormalities, the absence of RA signaling transduced by either receptor resulted in a delay in mammary gland tumorigenesis. In the RARα1-null model, the reduction observed in the mammary stem cell-containing compartment might be a factor in the delay in tumor formation by the *Wnt1* oncogene, but the exact mechanism responsible for the pro-oncogenic property of RARα1 in this context remains to be determined. On the other hand, absence of RARβ led to a remodeling of the stroma during tumor progression induced by the *Erbb2* oncogene that was marked by a decrease in angiogenesis, in the recruitment of inflammatory cells and in the number of myofibroblasts \[[@r16]\]. In agreement with this observation, tissue recombination experiments demonstrated that the presence of RARβ in the stromal compartment is essential for the growth of mammary carcinoma, and that RA-dependent activity of the Cxcl12/Cxcr4/Erbb2 signaling axis played a significant role in this process. Together, these studies suggest that retinoid-based approaches for the prevention and treatment of breast cancer should be re-evaluated and that a better understanding of the mechanisms of retinoid action in mammary gland tumorigenesis is required to achieve this goal.

In the current study, we further tested the specificity of the RAR/oncogene interaction in the development of mammary gland carcinoma using bigenic mice generated by crossing the RARβ-null mice with the MMTV-*Wnt1* transgenic mice. The *Wnt1* oncogene targets mammary stem cells or early progenitor cells as transformation cells \[[@r21]\]. Accordingly, *Wnt1*-induced tumors show a co-existence of both luminal cells and basal/myoepithelial cells, which is reminiscent of human basal-like breast cancer that is associated with poor prognosis and lack of effective treatment \[[@r22]\]. *Wnt1*-induced tumors have also been reported to have abundant activated stroma that correlated with more aggressive tumor development \[[@r23]\]. Therefore, we sought to investigate the influence of RARβ on *Wnt1*-induced mammary carcinoma. We found that inactivation of RARβ resulted in a protective effect against *Wnt1*-induced mammary gland tumorigenesis, abrogation of Wnt signaling in both the epithelial and stromal compartments, and suppression of epithelial-mesenchymal transition (EMT) in the tumors. Our work indicates therefore that RARβ is essential for the bi-directional interaction between tumor and stromal cells and that RARβ specific antagonists may represent a novel therapeutic strategy to treat poor outcome breast cancer.

Materials and Methods
=====================

Mice
----

All animals were FVB/NJ background and housed in a pathogen-free facility at McGill University and were given a standard rodent diet and water ad libitum. MMTV-*Wnt1* mice were purchased from the Jackson Laboratory \[[@r24]\]. To determine the initiation of mammary tumor formation, mice were palpated weekly (sensitive to 1-mm tumor masses). All mouse manipulations were performed in accordance with the McGill Facility Animal Care Committee and the Canadian Council on Animal Care.

Cell culture
------------

Mouse mammary fibroblast cell lines were generated from the MMTV-*Wnt1* animals as described before \[[@r16]\]. To generate tumor cells, tumors were dissected, mechanically dissociated, and forced through 40 μm mesh. Viable cells were plated, grown in DMEM supplemented with 10% FBS and penicillin/streptomycin. The cells had virtually identical epithelial morphology under microscope and had similar cell surface marker expression. All cultured cells were maintained in DMEM supplemented with 10% FBS and incubated in 5% CO~2~ at 37^o^C. The fibroblasts were treated with all-trans RA (Sigma \#R2625) at a concentration of 0.5 μM for 2 days to generate conditioned media. Conditioned media from *Rarb*-null or wild-type mouse mammary gland fibroblasts were also supplemented with either IGF-1 or anti-IGF-1 antibody (R&D Systems) at final concentrations of 10 ng/ml and 40 μg/ml, respectively.

Reactive stroma index
---------------------

Hematoxylin and eosin staining was carried out in the histology service core of the Goodman Cancer Research Centre. Stained sections were examined in a blinded manner and scored for the reactive stroma index based on the percentage contribution of a stroma area in tumor mass (i.e., 0--10% stroma area = 0, 11--20% stroma area = 1, and so on, \>50% stroma area = 5). The average of five areas was used as the reactive stroma index for each sample.

Histological analyses
---------------------

Immunohistochemical analyses were performed on 4-μm formalin-fixed paraffin-embedded sections of tumors from mice killed one month after tumor initiation. Immunostaining was done using the VECTASTAIN avidin-biotin complex kit (Vector Laboratories) as previously described \[[@r25]\]. Immunofluorescence staining was conducted on formalin-fixed paraffin-embedded tumor sections. Five random areas per section from 3 separate sections obtained from different mice for each group were analyzed. The following dilutions of primary antibodies were used: rabbit polyclonal anti--human-RARβ (Abcam), 1:100; mouse monoclonal anti-human Ki67 (clone B56; BD Pharmingen), 1:100; rabbit polyclonal anti-mouse Wnt1 (Upstate), 1:50; rabbit polyclonal anti--human-caspase-3 (Cell Signaling), 1:50; rat monoclonal anti--mouse-CD31 (clone Mec13.3; Biocare), 1:50; mouse monoclonal anti-CD45, 1:100, and rabbit polyclonal anti-mouse collagen I, 1:100 (Abcam Inc.), horse polyclonal anti-human smooth muscle actin-α (α-SMA) (Abcam), 1:100, ; rabbit polyclonal anti-mouse IGF1 (Abcam), 1:100. For the negative control, primary antibody was replaced with non-immunized rabbit or mouse IgG (Vector Laboratories). All images were taken with 10× objectives (100× magnification). For multiple antigen labeling the VECTASTAIN System (Vector ABCDAB kit, Vector ABC-AP kit, and Vector ImmPRESSNovaRED and VIP kit) (Vector Laboratories) was used. Peroxidase and alkaline phosphatase substrates were used to develop color of the antigens with different localization. To compare positive cell numbers, 10 random fields per section were documented in the Aperio Image System and were analyzed using the Spectrum software (Aperio Technologies). Mean values shown beside the corresponding images were determined from results from at least six different mice for each genotype.

Apoptosis analysis
------------------

The number of TUNEL-positive or caspase 3-postive tumor cell nuclei was calculated relative to the total number of 1,000 cancer cell nuclei, which was analyzed with the Spectrum software. Mean values were determined from results from at least six different mice.

Western blotting
----------------

Lysates were prepared from the mammary tumors of three *Rarb*^-/-^ and three wild-type mice. Antibodies against phospho-GSK3β (Ser9, 07-835), GSK3β (07-1413), Snail (ABD38), phospho-AKT (9611), and AKT (9272) were purchased from Cell Signaling Technology. Antibodies against RARβ (SC-552), Wnt-1 (SC-5630), Wisp1 (SC-13316), E-cadherin (SC-7870), integrin α5 (SC-10719), LAMA1 (SC-56145), vimentin (SC-373717), cytokeratin (SC-529), IGF1 (SC-7144), IGFBP5 (SC-6006), and actin (SC-1616) were purchased from Santa Cruz Biotechnology.

Laser capture microdissection, RNA extraction and linear amplification
----------------------------------------------------------------------

All tissues included in this study were re-examined by an animal pathologist dedicated to the project. Tissue specimens were micro-dissected into epithelium and stroma using a PixCell IIe laser micro-dissection (LCM) system (Arcturus). All micro-dissections were performed within two hours following tissue staining. Total RNA was extracted from each population of micro-dissected cells using a guanidinium isothiocyanate (GITC) extraction protocol. Briefly, LCM caps were incubated for 5 minutes (room temperature) in 200 μl GITC extraction buffer (4 M GITC, 25 mM sodium citrate pH 7.0, 0.1 M β-mercaptoethanol, 0.5% N-lauroylsarcosine) supplemented with 1.6 μl β-mercaptoethanol. Subsequently, 20 μl of 2 M NaOAc, pH 4.0, 220 μl of water-saturated phenol and 60 μl of chloroform-isoamyl alcohol (23:1) were added to the extraction buffer. Following a 15 minute incubation on ice and centrifugation (12,000 rpm, 15 minutes) the aqueous phase was removed and RNA was precipitated with 2 μl glycogen (GenHunter, Nashville, Tennessee, USA) and 200 μl isopropanol. Samples were placed at - 80°C for 30 minutes and centrifuged at 4°C (12,000 rpm) for 30 minutes to pellet RNA. Pellets were washed with 70% ethanol, air-dried and subjected to DNase I treatment (Roche, Basel, Switzerland). DNAse treatment was performed in the presence of an RNase inhibitor (Invitrogen, Carlsbad, California, USA). Subsequently, samples were re-extracted as described above and re-suspended in 10 μl of diethylpyrocarbonate-treated water. RNA was quantified using a RiboGreen assay (Molecular Probes, Carlsbad, California, USA). Subsequently, 2 to 4 ng of total RNA was subjected to two rounds of T7 linear amplification using Ambion Amino Allyl MessageAmp kit (Ambion, Austin, Texas, USA) and labeled with Cy3 and Cy5 dyes according to the manufacturer\'s procedure. Prior to microarray hybridizations, amplified products were quantified using a spectrophotometer (Nanodrop, Wilmington, Delaware, USA) and analyzed using a BioAnalyzer to assay for quality (Agilent Technologies, Santa Clara, California, USA).

RNA microarrays
---------------

SurePrint G3 mouse Genome 8x60 K arrays (Agilent Technologies, product G4852A) were used for all experiments. RNA samples (500 ng) were subjected to fragmentation followed by 18 hours hybridization, washing, and scanning (Agilent Technologies, model G2505B) according to the manufacturer\'s protocol (manual ID \#G4140-90030). Samples were hybridized against Universal mouse Reference RNA (Stratagene, ID \#750600, La Jolla, California, USA). Duplicate hybridizations were performed for all samples using reverse-dye labeling. Microarray data were feature extracted using Feature Extraction Software (v. 7.11) from Agilent with the default parameters. Raw data were uploaded to the NCBI Gene Expression Omnibus database (GEO, GSE\#56391). Outlier features on arrays were flagged by the software. Arrays were required to have an average raw signal intensity of 1,000 in each channel, and a signal to noise ratio above 16 per channel. MvA plots were examined for signs of hybridization or labeling problems. Replicate arrays were required to have a concordance above 0.944. This level was established empirically using sets of known good replicate arrays in our database.

Real-time PCR for Igf1 expression
---------------------------------

Total RNA from LCM samples was amplified using Amino Allyl MessageAmp II aRNA Kit (Ambion \#1753). cDNA was made from 2 μg of RNA by reverse transcription with Oligo(dT) primer, dNTPs, 5X 1st strand buffer, DTT, RNase inhibitor, and Superscript II RNase H Reverse Transcriptase (Invitrogen). cDNA was amplified by qRT-PCR using the specific forward 5'-TTCTACCTGGCGCTCTGCTTGC and reverse 5'-CCCTCCGAATGCTGGAGCCATA primers, a QuantiTect SYBR Green PCR Kit (Qiagen) and a LightCycler instrument (Roche) following the Qiagen software protocol.

ELISA
-----

Submandibular venous blood was collected into microcentrifuge tubes using a sterile lancet (Medipoint, Mineola, NY) according to the manufacturer's instructions. Whole blood was centrifuged at 2500×*g* for 20 minutes at 4°C to collect serum, which was then stored at −80°C. Serum was processed for ELISA of IGF-1 (R&D Systems, Minneapolis, MN) according to the manufacturer's protocol. Serum IGF-1 levels are reported in ng/ml. An IGF-1 control sample, with aliquots stored at -80°C, was included on each plate, and all data are reported using simple ratio normalization to the initial reading of the control sample.

Statistical analysis
--------------------

Two-tailed paired Student *t* test was calculated by Excel software. Prism software was used for one or 2-way ANOVA and log-rank (Mantel-Cox) test.

Results
=======

Global ablation of Rarb in mice delays Wnt1-induced mammary gland tumorigenesis and alters the stromal compartment
------------------------------------------------------------------------------------------------------------------

To further study the potential role of RARβ as a tumor promoter in mammary gland tumorigenesis, we used the well-characterized mouse model of human breast cancer expressing the oncogene *Wnt1* in combination with the *Rarb*-null allele \[[@r18],[@r24]\]. While both *Rarb*^-/-^ and wild-type mice displayed similar high penetrance for tumor formation (78% and 83%, respectively), the *Rarb*^-/-^ mice showed a significant delay (\~12 weeks, P\<0.01) in tumor formation when strong expression of *Wnt1* was driven by the MMTV promoter ([Figure 1A](#f1){ref-type="fig"}). In addition, the tumors in mice with the *Rarb*^-/-^ genetic background grew at a significantly slower rate than tumors induced in their wild-type siblings (6.3 vs 4.0 weeks, P\<0.05) ([Figure 1B](#f1){ref-type="fig"}). Consistent with these results, examination of mammary gland sections taken from MMTV-*Wnt1* mice by immunohistochemistry (IHC) showed a significant decrease in Ki67 labeling in MMTV-*Wnt1*/*Rarb*^-/-^ tumor cells compared to MMTV-*Wnt1* wild type tumor cells ([Figure 1C](#f1){ref-type="fig"}). On the other hand, TUNEL staining showed significantly increased apoptotic cell death in the tumors growing in *Rarb*-null animals ([Figure 1D](#f1){ref-type="fig"}). Concurrently, caspase 3 IHC also displayed more apoptotic enzyme activity in *Rarb*-null tumor cells ([Figure 1E](#f1){ref-type="fig"}). As the absence of RARβ had a major impact on the composition of the stroma surrounding ERBB2-induced mammary tumors \[[@r16]\], we next measured the grade of stromal activation in *Wnt1*-induced tumors generated in the *Rarb*^-/-^ and wild type genotypes. Indeed, the MMTV-*Wnt1* tumors in the wild type background had a 31% higher reactive stroma index than tumors developing in *Rarb*-null siblings (3.8±0.7 vs 2.9±1.1 P\<0.05) ([Figure 1F](#f1){ref-type="fig"}). To determine whether the absence of RARβ affected the growth potential of cancer associated fibroblasts (CAFs), we generated stromal fibroblasts from control and *Rarb*^-/-^ mammary glands as previously described \[[@r16]\] and compared their growth rate *in vitro*. In low serum conditions (2% FBS), the *Rarb*^-/-^ fibroblasts displayed growth arrest whereas wild type fibroblasts survived and divided indicating that *Rarb*^-/-^ CAFs have less aggressive malignant properties that persists *ex vivo* ([Figure 1G](#f1){ref-type="fig"}).

![Ablation of *Rarb* suppresses Wnt1-induced mammary tumorigenesis and affects the composition of the stroma.\
(a) *Rarb*-null mice show a significant delay in tumor formation when the expression of *Wnt1* is driven by the MMTV-LTR promoter (n=25 *Rarb*^-/-^ and 26 wild-type mice). Insets: Western blot analysis of RARβ and Wnt1 expression in wild-type and *Rarb*^-/-^ mice; immunostaining of RARβ in tumor (T) and stroma (S) in wild-type tissue. (b) Tumor growth rate as measured as time to end point (tumor burden total of 2 cm^3^), n=24. (c) Cell proliferation rate was identified by Ki67 expression (red signal), which is significantly lower in the tumors from *Rarb* null mice. (d) TUNEL analysis showed significantly increased apoptotic cells in *Rarb* null mice. (e) Caspase 3 is detected in tumor cells with a significant increase in *Rarb* null animals. (f) Mammary tumor paraffin sections stained for collagen 1 (Col3a1) show a decrease in matrix stiffness. Quantification of reactive stroma index (RSI) is shown on the right panel. (g) Growth rate of CAFs generated from control and *Rarb*-null mammary glands *in vitro*.. For panels c, d and e, scale bars, 50 and 20 μm for low (left) and high magnification (right), respectively. For panel f, scale bar, 50 μm. \**P* \< 0.05, \*\**P* \< 0.01, \*\*\**P* \<0.001](nrs-12-004-g1){#f1}

Loss of *Rarb* results in remodeling of the stromal compartment in Wnt1-induced mammary gland tumors
----------------------------------------------------------------------------------------------------

Stroma may initiate a desmoplastic reaction that includes activation of CAFs and trans-differentiation of tumor or epithelial cells into myofibroblasts, infiltration of immune cells, increased secretion of growth factors and cytokines as well as elevated matrix synthesis and remodeling that manifests as matrix stiffening. Analysis of differential gene expression in the stroma and epithelial compartments using laser capture microdissection (LCM) showed that several genes associated with activation of fibroblasts such as *Col3a1*, *Col5a1*, *Col5a3*, *Col6a2*, *Col6a3*, *Fn1*, *Fap* and *Vim* are down-regulated in the stromal compartment of MMTV-*Wnt1*/*Rarb*^-/-^ animals compared to their wild type siblings ([Figure 2A](#f2){ref-type="fig"}). Morphologically, IHC analysis indicated reduced collagen deposition in MMTV-*Wnt1*/*Rarb*^-/-^ tumor sections ([Figure 2B](#f2){ref-type="fig"}), indicating decreased matrix stiffening. Moreover, significantly decreased smooth muscle actin (α-SMA) positive cells were found in MMTV-*Wnt1*/*Rarb*^-/-^ tumor sections ([Figure 2C](#f2){ref-type="fig"}), further indicating that fibroblast activation was suppressed in these animals. In addition, a reduction in the recruitment of inflammatory cells as measured by CD45 staining was observed in the peritumoral stroma of *Rarb*-null mice relative to their wild type siblings ([Figure 2D](#f2){ref-type="fig"}). LCM-RNA microarray data also showed that several genes involved in angiogenesis, including *Angpt2*, *Angptl4* and *Bmper*, were down regulated in the stroma of MMTV-*Wnt1*/*Rarb*^-/-^ animals ([Figure 2A](#f2){ref-type="fig"}). Consistent with the gene expression data, non-uniformly distributed blood vessels with irregular shape were observed in sections obtained from the mammary tumors of wild type mice and stained for CD31 expression ([Figure 2E](#f2){ref-type="fig"}). These abnormal blood vessels were inappropriately branched, dilated and usually ended blindly. In contrast, we found significantly fewer blood vessels in the *Rarb*-null tumors.

![Loss of *Rarb* alters the gene expression profile of the stromal compartment and its composition.\
(a) Differential gene expression analysis of the microdissected stromal compartment of MMTV-*Wnt1* and MMTV-*Wnt1*/*Rarb*^-/-^ tumors. Data are presented as relative fold change (log2) *vs.* wild-type stroma. (b) Mammary tumor paraffin sections stained for collagen 1 (COL3A1) show a decrease in matrix stiffness and indicate reduced activity of the CAFs in the *Rarb*-null tumor microenvironment. Quantification of positive area is shown on the right panel. (c) Paraffin sections stained for α-SMA (red, cytoplasmic). Quantification of positive area is shown on the right. (d) Mammary tumor paraffin sections stained for CD45 demonstrate a decreased infiltration of inflammatory cells in the *Rarb*-null stroma. Quantification of positive cells is shown on the right panel. (e) Mammary tumor paraffin sections stained for CD31 demonstrate a reduction of angiogenesis in the *Rarb*-null tumor microenvironment. Quantification of positive area is shown on the right panel. For all panels, scale bars, 50 and 20 μm for low (left) and high magnification (right), respectively.](nrs-12-004-g2){#f2}

Inhibition of epithelial-mesenchymal transition in Wnt1-induced *Rarb*-null tumors
----------------------------------------------------------------------------------

Besides activation from local fibroblasts, emerging evidence indicates that matrix-producing myofibroblasts also arise through epithelial-mesenchymal transition (EMT) \[[@r26]\]. Interestingly, LCM-mRNA microarray data showed that several genes involved in EMT, such as *Ecm2*, *Mmp3*, *Fgf2*, and *Igf1*, were significantly down regulated in MMTV-*Wnt1*/*Rarb*^-/-^ tumors ([Figure 3A](#f3){ref-type="fig"}). We observed that the expression of markers of epithelium undergoing EMT, including E-cadherin, cytokeratin and laminin, were significantly increased at the protein level, whereas the expression of vimentin and integrin (ITGA5) were decreased in MMTV-*Wnt1*/*Rarb*^-/-^ animals ([Figure 3B](#f3){ref-type="fig"}). This observation was further confirmed by immunofluorescence showing higher E-cadherin levels in sections obtained from *Rarb*^-/-^ mice ([Figure 3C](#f3){ref-type="fig"}), as well as increased translocation of β-catenin into the nucleus in wild type cells ([Figure 3D](#f3){ref-type="fig"}). Collectively, these data indicate that *Rarb* ablation results in suppression of EMT in the *Wnt1*-induced tumors.

![Inhibition of epithelial-mesenchymal transition in Wnt1-induced *Rarb*-null tumors.\
(a) Differential gene expression analysis of the microdissected epithelial compartment of MMTV-*Wnt1* and MMTV-*Wnt1*/*Rarb*^-/-^ tumors. Data are presented as relative fold change (log2) *vs.* wild-type stroma. (b) Western blot analysis of markers of epithelium undergoing EMT in lysates derived from MMTV-*Wnt1* and MMTV-*Wnt1*/*Rarb*^-/-^ tumors. (c) Expression of E-cadherin (red) and Ki67 (green) as monitored by immunofluorescence in MMTV-*Wnt1* and MMTV-*Wnt1*/*Rarb*^-/-^ tumors. (d) Nuclear localization of β-catenin (green) as monitored by immunofluorescence.](nrs-12-004-g3){#f3}

Down regulation of the IGF1/AKT axis in Wnt1-induced *Rarb*-null tumors
-----------------------------------------------------------------------

IGF-1 plays a central role in cell growth, differentiation, survival, transformation and metastasis, and deregulation of the IGF signaling pathway is well recognized as a key contributor to the progression of multiple cancers including mammary gland tumors. The IGF-1 signaling axis can also affect EMT. IGF-1 binds IGF1R to induce PI3K and activates AKT to repress GSK3β. GSK3β is a repressor of β-catenin and Snail able of inhibiting E-cadherin expression and subsequently promotes EMT and tumor progression. While we observed a reduction in the expression of *Igf1* in the tumor compartment, IGF-1 is also produced by stromal cells. Western blotting using protein lysates obtained from whole tumors showed a decrease in endogenous IGF-1 levels and an increase in the expression of *IGFBP5*, an antagonist of IGF signaling, in the *Rarb*-null samples ([Figure 4A](#f4){ref-type="fig"}). We next investigated whether the reduced levels of IGF-1 had an impact on AKT expression and activity in the tumors. Indeed, tumors obtained from MMTV-*Wnt1*/*Rarb*^-/-^ animals displayed a small decrease in total AKT levels and a sharp reduction of phosphorylated AKT at serine 473 ([Figure 4A](#f4){ref-type="fig"}). In addition, we found increased phosphorylation of GSK3β and decreased expression of Snail, both of which are downstream components of the IGF-1/AKT axis ([Figure 4A](#f4){ref-type="fig"}). While no significant difference in the serum concentration of IGF-1 between *Rarb*-null animals and their wild type siblings was detected by ELISA ([Figure 4B](#f4){ref-type="fig"}), we found significantly lower IGF-1 concentrations in the supernatants collected from *Rarb*-null CAFs in culture compared to the supernatants obtained from wild type fibroblasts ([Figure 4C](#f4){ref-type="fig"}). These results indicate that changes in local IGF-1 levels are not due to a systemic effect of the absence of RARβ but intrinsic to the tumor microenvironment. Furthermore, retinoic acid induced the expression of IGF-1 mRNA from wild type fibroblasts ([Figure 4D](#f4){ref-type="fig"}). Finally, tumor cells isolated from the *Wnt1*-induced tumors in wild type mice were cultured in the presence of conditioned media obtained from *Rarb*-null and wild type CAFs to measure growth rate. *Wnt1*-induced tumor cells cultured in the presence of conditioned media derived from *Rarb*-null fibroblasts showed a significant decreased cell growth rate ([Figure 4E](#f4){ref-type="fig"}). In addition, immune-neutralization of IGF-1 in the conditioned medium derived from wild-type fibroblasts also reduced cellular growth rate, whereas supplementation of IGF-1 to the conditioned medium obtained from *Rarb*-null fibroblasts reversed the slow growth phenotype ([Figure 4E](#f4){ref-type="fig"}). Taken together, these data indicate that in the absence of RARβ, reduced expression of IGF-1 and activity of its downstream signaling pathway contribute to attenuate EMT in *Rarb*-null tumors.

![Down regulation of the IGF1/AKT axis in Wnt1-induced *Rarb*-null tumors.\
(a) Western blot analysis of components of the IGF-1/AKT signaling axis in lysates derived from MMTV-*Wnt1* and MMTV-*Wnt1*/*Rarb*^-/-^ tumors. (b) Serum concentration of IGF-1 in *Rarb*-null and wild-type mice. N=5 for each group. (c) IGF-1 concentrations in the supernatant collected from *Rarb*-null CAFs in culture compared to the supernatant obtained from wild type fibroblasts. N=5 for each group. (d) Effect of RA (100 nM) on the expression of *Igf1* mRNA from wild-type fibroblasts. N=4 for each group. (e) Growth curves of tumor cells cultured in the presence of conditioned media derived from wild-type (WT) or RARβ^-/-^ mammary fibroblasts and immunoneutralized with an antibody (Ab) against IGF-1 or supplemented with IGF-1. \**P* \< 0.05, \*\*\**P* \< 0.001.](nrs-12-004-g4){#f4}

Discussion
==========

The antitumor activities of retinoids and their receptors have been investigated extensively and one of the receptors, RARβ, has been suggested to possess many of the functional characteristics of a tumor suppressor \[[@r13]\]. However, previous work from our laboratory showed that in the context of the whole organism, *Rarb* is not a tumor suppressor, but rather that its presence is required for the full oncogenic potential of *Erbb2/neu* \[[@r16]\]. Tissue recombination studies indicated that it is the absence of RARβ in the tumor microenvironment, rather than the status of *Rarb* in mammary epithelial cells, that affects the initiation and progression of *Erbb2/neu*-induced mammary gland carcinoma. In the current study, we monitored the influence of *Rarb* deletion on the induction of mammary tumors by the *Wnt1* oncogene to test whether the absence of retinoid signaling via RARβ affects mammary tumor formation driven by a different oncogenic pathway. As previously observed with the MMTV-*erbb2/neu* model, ablation of *Rarb* in the MMTV-*Wnt1* model showed extensive remodeling of the stroma during tumor progression through suppression of the activation and trans-differentiation of CAFs, reduction in matrix stiffness, decreased tumor angiogenesis and reduced inflammatory cell infiltration. Despite these similarities, the molecular mechanism underlining the interactions by which *Rarb* confers its effects on tumor cells is distinct between the two mouse models of human breast cancer. Clinically, these results imply that modulation of RARβ activity could have important applications to treat breast cancers of different cellular origin and/or driven by distinct oncogenic pathways.

In the *Wnt1* model, oncogenic transformation has been proposed to target mammary gland stem cells or early progenitor cells. Therefore, *Wnt1*-induced tumors are morphologically composed of a variety of cell types, including distinct tumor luminal epithelial, basal/myoepithelial cells and host-derived stroma cells \[[@r27]-[@r29]\]. Wnt1 ligand produced by tumor cells can directly activate the surrounding stromal cells in a paracrine manner \[[@r30]\]. In return, stromal cells can affect tumor cells by expressing IGF-1, which activates IGF1R signaling in tumor cells \[[@r31]\]. This important molecular cross talk between tumor and stromal cells is severely weakened in the absence of RARβ. Deletion of *Rarb* down-regulated Wnt1 signaling as indicated by E-cadherin expression and nuclear localization of β-catenin resulting in lower IGF-1 expression in the stroma and suppression of the IGF-1/AKT axis in the tumor cells. Notably, reports demonstrated the importance of Wnt1 signaling in mammary stroma of human breast cancer which has been linked to EMT and poor clinical outcome \[[@r32]-[@r34]\].

Besides affecting stromal cells, Wnt1 ligand secreted by luminal epithelia can also target myoepithelial cells \[[@r30]\]. A recent report indicates that the *Wnt1*-driven tumor growth can be inhibited by a soluble Wnt receptor inhibitor \[[@r31]\]. The mechanism through which this effect is mediated involves the induction of IGFBP5, an antagonist of IGF signaling that has been shown to facilitate tumor growth by paracrine communication. The regulation of IGFBP5 is mediated by the β-catenin-dependent Wnt pathway. Strikingly, we observed that *Igfbp5* was up-regulated about 2-fold in transcript levels while *Igf1* was down regulated in the *Rarb*-null tumors. It has also been reported that overexpression of IGFBP5 results in an increase in apoptotic cells in the mammary glands, whereas mice with mutant *Igfbp5* exhibit a decrease in apoptotic cells and a delay in mammary gland involution \[[@r35]-[@r37]\]. IGF-1 is a known growth and survival factor in mammary epithelial cells, and hyperactive IGF-1 signaling is found in various human tumors including breast cancer \[[@r38],[@r39]\]. Moreover, IGF1R activation has been shown to induce EMT by a PI3K/AKT-mediated mechanism and a concomitant increase in the expression of Snail and suppression of E-cadherin expression \[[@r40]-[@r45]\]. In agreement with these reports, we observed increased and decreased levels of E-cadherin and Snail proteins, respectively, as well as decrease cell proliferation and more apoptosis in *Rarb*-null tumors. Accordingly, both suppression of Wnt1 signaling pathway and repression of the IGF1/AKT axis in the absence of *Rarb* have an important negative impact on CAF activation and EMT in the *Wnt1*-induced tumors.

Conclusions
===========

The failure of retinoid-based therapies to treat breast cancer led us and others to hypothesize that retinoic acid receptor isoform might have distinct and perhaps antagonistic functions in mammary gland development and in oncogenesis. Indeed, while activation or inhibition of the RARα isoform in mice are consistent with the anti-proliferative action of this receptor \[[@r17],[@r46]\], the activity of the RARβ and RARγ suggests that these isoforms act as proto-oncogenes in the context of the whole gland \[[@r16],[@r46]\]. In this work, we extended these findings by demonstrating that *Rarb* is crucial for the interaction between tumor cells and stromal cells. We found that *Rarb* expression has an important impact on Wnt signaling in both tumor and stromal cells. Specifically, inactivation of *Rarb* resulted in suppression of Wnt1 signaling which further inhibited the IGF-1/AKT/Snail/E-cadherin pathway and consequently repressed EMT ([Figure 5](#f5){ref-type="fig"}). Since *Wnt1*-induced tumors in the mouse resemble triple negative breast cancer or basal-like breast cancer in which the Wnt and IGF-1 signaling pathways are known to be activated, this work suggests that specific RARβ antagonists could have useful clinical application in the treatment of poor outcome breast cancer.

![*Rarb* is crucial for the interaction between tumor cells and stromal cells.\
Schematic representation of perturbed signaling pathways in *Wnt1*-induced tumors and their microenvironments in wild-type and *Rarb*^-/-^ mice. Loss of *Rarb* leads to remodeling of the stroma (bars), reduced Wnt-1 signaling in CAFs, decreased IGF-1 levels and inhibition of EMT in the tumor as assessed by lower expression of Snail, decreased and increased AKT and GSK-β phosphorylation, respectively.](nrs-12-004-g5){#f5}
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